Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02993614 · ClinicalTrials.gov registry record
Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors
A clinical trial, sponsored by AstraZeneca.
- Completed
- Registry status
- 99,999
- Enrollment target
NCT02993614 is a clinical trial that has completed, run by AstraZeneca. The registered enrollment target is 99,999 participants.
The verdict
NCT02993614 has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 99,999 participants
- Enrollment target
Study Summary
CVD-REAL is a multinational, observational cohort study in patients with type 2 diabetes mellitus evaluating the comparative effectiveness of initiating treatment with a sodium-glucose co-transporter-2 (SGLT-2) inhibitor versus another glucose-lowering drug. This study will compare the risk of all-cause mortality and clinically relevant cardiovascular (CV) outcomes respectively in patients who are new users of SGLT-2 inhibitors with those who are new users of other glucose-lowering drugs. CVD-REAL is aiming to collect data from approximately 4 million patients overall, from twelve countries across three major world regions.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99,999 participants |
| Start Date | 2017-11-30 |
| Est. Completion | 2020-12-17 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02993614
The ClinicalTrials.gov registry entry for NCT02993614 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 99,999 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02993614 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02993614 about?
NCT02993614 is a clinical study titled "Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors". CVD-REAL is a multinational, observational cohort study in patients with type 2 diabetes mellitus evaluating the comparative effectiveness of initiating treatment with a sodium-glucose co-transporter-2 (SGLT-2) inhibitor versus another glucose-lowering drug. This study will compare the risk of all-c...
What is the current status of trial NCT02993614?
This trial is currently completed. The enrollment target is 99,999 participants. The study started on 2017-11-30. Estimated completion is 2020-12-17.
Who is sponsoring clinical trial NCT02993614?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.